key: cord-0994033-vr5yonqz
authors: Messali, Serena; Bertelli, Anna; Campisi, Giovanni; Zani, Alberto; Ciccozzi, Massimo; Caruso, Arnaldo; Caccuri, Francesca
title: A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
date: 2021-08-10
journal: J Med Virol
DOI: 10.1002/jmv.27247
sha: 9f397334fa32cc23b3ba6e56ee2faa4c9a436419
doc_id: 994033
cord_uid: vr5yonqz

In this study we show a 7-individual cluster belonging to the SARS-CoV-2 B.1.621 lineage, imported in Italy by traveler from abroad This article is protected by copyright. All rights reserved.

). Figure 1B shows the key mutations in the SARS-CoV-2 B.1.621 Spike protein.

In this study, we isolated for the first time the virus from the sample of the earliest positive patient and carried out a neutralization assay using the isolated virus soon after confirmation of its identity by WGS, and human sera collected between 10 and 20 days after the administration of the second dose of the BNT162b2 vaccine, which occurred 3 weeks after the first immunization. All sera efficiently neutralized the SARS-CoV-2 B.1.621 isolate ( Figure 1C ), demonstrating that this VOI is not a concern for vaccine efficacy. Indeed, neutralization of SARS-CoV- 

The authors declare that there are no conflict of interests. Horizontal lines and the numbers over the bars indicate geometric mean titers (GM). The I bars indicate 95% confidence intervals. Statistical analysis was performed using the paired t test and two-tailed p values were calculated

New SARS-CoV-2 variants-clinical, public health, and vaccine implications

SARS-CoV-2 Variant Classifications and Definitions

European Centre for Disease Prevention and Control (ecdc)

SARS-CoV-2 variants of concern as of

Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2